Clinical operations note: globus-medical-a-quality-inspector039s-honest-take-on-the-excelsiusgps-nevro-acquisition-90

Frequently Asked Questions About Globus Medical, ExcelsiusGPS, and Surgical Robotics

Look, I work in quality and compliance here at Globus Medical. I review the specs and documentation that go out the door. I don't write the marketing copy. So when people ask me questions about our products—especially after the big announcements—they usually want the no-nonsense version.

Here's what I'm asked most often, along with the honest answers I can give based on what I've seen in audits and product releases.

What is the actual installed base of the ExcelsiusGPS robot as of 2025?

That's a tricky number because the definition of "installed" changed a bit last year. Some systems are in the middle of final calibration at customer sites. So, the official public figure from Q3 2024 was around 100 systems. I can tell you that number has grown slightly since then, but the more important metric is the active utilization rate—how many cases are actually being routed through those systems. We're seeing a steady increase, which is the number we really care about internally. (Honestly, the public 'installed base' number is just a lagging indicator.)

Did Globus Medical acquire Nevro in 2025? What's the deal with that?

Yes, the acquisition officially closed in early 2025. It wasn't something that happened overnight. We'd been looking at the pain management space for a while. The core logic was simple: our forte is spinal hardware and navigation, but a huge chunk of the post-surgical patient journey involves pain management. Nevro's Senza system fits right into that recovery path. From a quality perspective, integrating their hardware into our regulatory framework (especially the 510(k) clearances) has been… busy. (Ugh, the documentation audits are still ongoing.) But it gives us a more complete story for the surgical center buyers.

Is the surgical robot market becoming a monopoly for Globus?

No. Here's the thing: having a good robot doesn't mean you own the market. We have a very strong navigation system, but Medtronic's StealthStation and Stryker's Mako are entrenched in their respective specialties. I think the real competition isn't about who has the shiniest arm—it's about data integration. Can your robot talk to the patient monitoring system in the OR? Can it feed data into the hospital's EMR? That's where the race really is. I've seen three separate bidding wars this year where the winner wasn't the cheapest robot, but the one with the best API documentation. (Surprise, surprise.)

How does a pulse oximeter actually work? I keep hearing about accuracy issues.

I hear this question a lot in our training sessions. A pulse oximeter works by shining two specific wavelengths of light (red and infrared) through a translucent part of the body—usually a fingertip. It measures how much of that light is absorbed by oxygenated vs. deoxygenated hemoglobin in the blood.

"The standard formula is the Beer-Lambert law. It's a spectrophotometry calculation. But the real-world accuracy depends heavily on the signal-to-noise ratio. Movement artifact is the enemy."

The criticism about accuracy is valid. Many devices (not just ours) struggle with pigmented skin and low perfusion states. We've put a lot of work into the algorithms for our own patient monitoring systems to try to reduce that variability. We're not perfect, but the latest revision (R2.4) improved motion tolerance by about 15% according to our internal tests.

What's the biggest mistake buyers make when spec'ing out patient monitoring systems?

They focus on the bedside monitor specs and forget about the network infrastructure. I can't tell you how many times I've reviewed a procurement plan that specifies a cutting-edge central monitoring station but then plans to run it over an older, flooded Wi-Fi 5 network. The data packets just get dropped. The monitor itself is great, but the end-user experience is terrible because the interface lags. We've had to reject installations because the hospital's network wasn't up to the spec we provided in the contract. That miscommunication costs everyone time. I said 'enterprise-grade network' in the requirements. They heard 'a decent Wi-Fi connection.' The result was a $22,000 project delay while they pulled new cables.

Is Globus Medical just overhyped? The stock seems up and down.

I can't give financial advice (and I'm not a trader). But I can tell you what I see from the quality side. The hype around the Nevro acquisition was real—it completes a strategic puzzle. However, integrating a new company's manufacturing quality is hard. The numbers said the merger would be accretive by H2 2025. My gut said to watch the Q1 scrap rate reports. Turns out there were some calibration dependencies between the Nevro implantables and our standard sterilization packaging that we didn't catch in the first month. We fixed it quickly, but it caused a minor inventory write-off. That's the kind of thing that creates temporary stock noise. (Thankfully, nothing that affected patient safety.)

How do you maintain quality across so many product categories (spine, monitoring, dental)?

By being boring. Seriously. We use a single, standardized document control system. The same template for a cleaning validation report for a spine reamer is the same template for a handpiece. It makes audits easier. The risk is that the standardization can be too rigid for innovative products. Every quarter, we have a meeting to argue about whether a new digital imaging system needs a different testing protocol. Usually, the data says it can fit into the existing framework. Sometimes, it can't. I rejected a proposal last month because the vendor tried to say their 'standard size' meant the same as our internal spec. It didn't. Their tolerance was 5mm; ours is 1mm for that specific dovetail connection. It's that attention to the boring details that avoids recalls.